Clinical Trial

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated October 1, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
There are unmet medical needs in patients who resist to EGFR TKIs, especially to osimertinib; APG-1252 shows synergy with osimertinib in both osimertinib treatment naïve and resistant cell lines. This study is to explore the safety and efficacy of the combination of APG-1252 and osimertinib in 3rd generation TKI resistant patients and 3rd generation TKI treatment naïve patients.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2019-06-26; most recent amendment 2025-09-30.
Status change: Recruiting → Active, Not Recruiting 2025-09-30
Status change: Not Yet Recruiting → Recruiting 2019-07-17
Trial Details
NCT Number NCT04001777
Lead Sponsor Ascentage Pharma Group Inc.
Collaborators: Suzhou Yasheng Pharmaceutical Co., Ltd.
Conditions EGFR Positive Non-small Cell Lung Cancer
Enrollment 80 participants
Start Date 2019-07-04
Primary Completion 2025-12 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-10-01